Viking Therapeutics (NASDAQ:VKTX - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07), Zacks reports. During the same quarter in the previous year, the firm earned ($0.26) earnings per share.
Viking Therapeutics Trading Down 3.2 %
Shares of NASDAQ VKTX traded down $0.83 during midday trading on Friday, hitting $24.84. 2,046,041 shares of the company's stock were exchanged, compared to its average volume of 4,050,074. The business's fifty day moving average price is $26.56 and its two-hundred day moving average price is $40.93. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -24.80 and a beta of 0.84. Viking Therapeutics has a 12-month low of $18.92 and a 12-month high of $81.86.
Insider Activity at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan purchased 1,240 shares of the firm's stock in a transaction dated Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Morgan Stanley dropped their price objective on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price objective for the company. Citigroup began coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 target price on the stock. Scotiabank assumed coverage on Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $89.50.
Read Our Latest Analysis on VKTX
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
